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A comparative study of the dentate gyrus in hippocampal sclerosis in epilepsy and dementia
Aims: Hippocampal sclerosis (HS) is long-recognized in
association with epilepsy (HSE) and more recently in the
context of cognitive decline or dementia in the elderly
(HSD), in some cases as a component of neurodegenerative
diseases, including Alzheimer’s disease (AD) and fronto-
temporal lobe dementia (FTLD). There is an increased risk
of seizures in AD and spontaneous epileptiform discharges
in the dentate gyrus of transgenic AD models; epilepsy can
be associated with an age-accelerated increase in AD-type
pathology and cognitive decline. The convergence between
these disease processes could be related to hippocampal
pathology. HSE typically shows re-organization of both
excitatory and inhibitory neuronal networks in the dentate
gyrus, and is considered to be relevant to hippocampal
excitability. We sought to compare the pathology of HSE
and HSD, focusing on re-organization in the dentate
gyrus. Methods: In nine post mortem cases with HSE and
bilateral damage, 18 HSD and 11 controls we carried
out immunostaining for mossy fibres (dynorphin), and
interneuronal networks (NPY, calbindin and calretinin)
on sections from the mid-hippocampal body. Fibre sprout-
ing (FS) or loss of expression in the dentate gyrus was
semi-quantitatively graded from grade 0 (normal) to
grade 3 (marked alteration). Results: Significantly more
re-organization was seen with all four markers in the HSE
than HSD group (P < 0.01). Mild alterations were noted in
HSD group with dynorphin (FS in 3 cases), calretinin (FS in
6 cases), NPY (FS in 11 cases) and calbindin (loss in 10
cases). In eight HSD cases, alteration was seen with more
than one antibody but in no cases were the highest grades
seen. We also noted NPY and, to a lesser extent, calretinin
labelling of Hirano bodies in CA1 of AD cases and some
older controls, but not in HSE. Conclusion: Reorganization
of excitatory and inhibitory networks in the dentate gyrus
is more typical of HSE. Subtle alterations in HSD may be a
result of increased hippocampal excitability, including
unrecognized seizure activity. An unexpected finding was
the identification of NPY-positive Hirano bodies in HSD
but not HSE, which may be a consequence of the relative
vulnerabilities of interneurons in these conditions.
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Introduction
Hippocampal sclerosis (HS) is a pathological change long-
associated with epilepsy and although not specific for
syndrome or seizure-type, is particularly associated with
mesial temporal lobe epilepsy (TLE) [1] from benign [2] to
drug-resistant types. Evidence suggests it is a relatively
common pathology, identified in 25% of all TLE patients
on MRI [3] and histologically confirmed in 33.6% and
30–40% of surgical [1] and post mortem (PM) epilepsy
cases [4,5] respectively. The pathological alterations of HS
in epilepsy (HSE) are well described [6], with consistent
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patterns of neuronal loss and gliosis centred on the CA1
subfield, with more variable loss from CA4 and other
subfields. More recently, the associated pathology involv-
ing the dentate gyrus has been better characterized with
dispersion of the granule cell layer (GCD) [7] and sprouting
of the mossy fibre axons [8] noted as common alterations.
In addition to loss of principal neurones, stereotypical
changes to hippocampal interneurons are well docu-
mented in surgical series, particularly in the dentate gyrus,
including loss and fibre sprouting [9–13].These alterations
to the dentate gyrus, which tend to occur synchronously,
are likely influenced by hippocampal seizures and excitabil-
ity rather than neuronal loss and they have been observed
in PM as well as surgical series of patients, where they may
be bilateral [14].
HS has also been increasingly recognized on imaging
and at PM in older and elderly patients, typically in the
absence of a seizure history, but in association with
memory impairment or dementia (HSD). The proposed
causes of HSD are heterogenous, and include anoxic-
ischaemic injury and neurodegenerative causes [15,16].
HSD has recently been linked to TDP-43 associated pathol-
ogy [17] in support of underlying degenerative mecha-
nisms. The prevalence of HSD in non-epilepsy, elderly PM
series is around 16% [18] and is bilateral in half of the
cases [16]. The pathological differences between HSE and
HSD have not been directly compared, in particular if
similar alterations in the dentate gyrus occur. Differences
between HSE and HSD would be useful in histopathological
evaluation, and may identify distinct mechanisms of
cell degeneration, and alterations specific to symptoms,
including seizures vs. memory loss. The aim of the current
study was to compare the dentate gyrus pathology in a
series of HSE with HSD PM cases, in particular with regard
to the patterns of GCD, mossy fibre sprouting and
interneuronal alterations.
Materials and methods
Cases were selected from the PM archives at the National
Hospital for Neurology and Neurosurgery, Queen Square
and from the Queen Square Brain Bank, Institute of Neu-
rology, London (details of all cases are available in a sup-
plemental file, Table S1). This study has been approved by
the Joint Research Ethics Committee of the Institute of
Neurology and appropriate consent was obtained from the
patient’s next of kin. We selected nine cases with bilateral
hippocampal sclerosis, as confirmed at PM, from patients
with epilepsy (HSE). Four patients were male and the
average age of onset of epilepsy was 11 years with mean
duration of disease of 53 years, and the average age of
death was 62 years (range 27–87 years). All the patients
had partial epilepsy syndromes, with a diagnosis of TLE in
four. We selected cases with low Braak stages [5], which
included six cases with stage 1 or 2, and three with stage
3. All the patients were residents at the National Society
for Epilepsy, Chalfont Centre, UK. For five patients, there
was a history of progressive cognitive decline reported in
later life [5].
We selected 10 cases of patients with Alzheimer’s
disease (AD) and diagnosis of HSD, defined as pyramidal
cells loss in the hippocampal formation that is out of pro-
portion to the AD neuropathological changes [19]. Seven
patients were male and the average age of death was 69
years (range 66–78 years). Nine cases were Braak stage 6
and one case Braak stage 5. In addition, we included eight
cases with fronto-temporal lobe dementia (FTLD) and a
diagnosis of HSD, which included four males. The average
age at death was 72 years (range 67–78 years) and the
diagnosis was FTLD-TDP type C in three cases, type B in
one case, type A in two cases, Pick’s disease in one case
and unspecified in one case [20]. In only one patient with
AD was there a history of seizure events following onset of
dementia, and in no case was epilepsy documented early
in life. In addition, 11 control cases were selected with no
history of AD or epilepsy; four were male and the mean
age was 55 years (range 36–68 years).
In all cases, one hemisphere was selected and a block
taken from the hippocampal body at the level best repre-
senting the HS pathology as evaluated on H&E and cresyl
violet/luxol fast blue preparations. Sections were cut at
7 μm thickness (and 14 μm for dynorphin labelling) for
immunohistochemistry. In brief, endogenous peroxidase
activity was blocked with 3% hydrogen peroxide (VWR
International, Pennsylvania, USA), sections were micro-
waved for 15 min in antigen retrieval masking buffer
(Vector, Burlingame, CA, USA) and washed in phosphate
buffered saline (PBS, Oxiod, Hampshire, UK). The primary
antibodies, anti-neuropeptide Y (NPY, 1:4000; Sigma,
USA), anti-calretinin (1:4000; Swant, Switzerland), anti-
calbindin (1:10 000; Swant), anti-dynorphin (1:50; AbD
Serotec, UK), GFAP (1:1500; Dako, Cambridge, UK) and
GFAP-δ (1:5000; Chemicon International, Temecula, CA,
USA) were diluted in Dako antibody diluent (Dako,
Glostrup, Denmark) and applied overnight. DAKO envi-
sion horse radish peroxidase (HRP, Dako) was used
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to detect labelling. Nuclei were counterstained with
Haematoxylin (VWR International). The catalysed signal
amplification was employed for the dynorphin staining
(see Liu et al. [21] for detailed protocol).
In addition, double labelling was performed on selected
HSD cases to further characterize NPY-immunopositive
Hirano bodies. In brief, sections were initially incubated
overnight with anti-MAP2 (1:750; Sigma), AT8 (1:1200;
Autogen Bioclear, UK), or SMI 31 (1:1000; Sternberger
Monoclonal Incorporation, USA) antibodies. On the fol-
lowing day, Dako Envision EnVision™ HRP solution was
applied for 30 min before fluorescein-labelled antibody in
tyramide signal amplification (TSA) buffer (1:500; Perkin
Elmer, UK) was applied for 8 min. The TSA system is a
sensitive detection system that has been used in previous
studies on PM human tissue [22,23]. Sections were
thoroughly washed before anti-NPY antibodies (1:4000)
were applied overnight. Rhodamine-labelled antibody in
TSA buffer (1:500; Perkin Elmer) was incubated on sec-
tions for 8 min at room temperature, before sections
were coverslipped in DAPI-mounting media (Vector).
Immunofluorescent-labelled sections were viewed under
a confocal laser scanning microscope (Zeiss LSM 710)
equipped with blue diode, argon and helium/neon lasers.
Qualitative assessment
In each case, the degree of hippocampal neuronal loss in
CA4 and CA1 and the pattern of granule cell dispersion
were assessed on the H&E section and graded (Table 1) in
addition to the distribution of astrocytic gliosis on GFAP
and delta-GFAP sections. The presence of mossy fibre
sprouting (MFS) and the expression patterns of calbindin,
calretinin and NPY in the dentate gyrus (in particular loss
of neuronal expression and abnormal fibre sprouting)
were assessed and graded as previously described and vali-
dated in studies of HSE (Table 1) [12–14,23]. The grading
was carried out independently by two observers with good
agreement (kappa scores between 0.65 and 0.74 for the
four markers), and agreement reached on all cases follow-
ing a joint review.
Quantitative assessment
In calbindin immunolabelled sections, quantitative analy-
sis of the distribution of positive cell labelling was carried
out as previously described [12]. In brief, images were cap-
tured at ×10 magnification on calbindin stained sections
with a Zeiss Axio microscope (Zeiss, Cambridge, UK). Up to
Table 1. Grading system for assessment of neuronal loss and evaluation of mossy fibre sprouting (MFS) on dynorphin staining and
alterations to inhibitory neuronal markers in the dentate gyrus
Grade 0 1 2 3
CA1 No neuronal loss Neuronal loss present but
incomplete (∼50–75%)
Majority of neurones lost
(>75%)
CA4 No neuronal loss Neuronal loss present but
incomplete (∼50–75%)
Majority of neurones lost
(>75%)
GCD Normal granule cell layer Mild dispersion Severe dispersion
Dynorphin Normal pattern: labelling of
the mossy fibre pathway in
CA4 and CA3
MFS in IML MFS in IML and OML
Neuropeptide Y Normal pattern: radial axonal
sprouts inconspicuous &
horizontal axonal network
in OML > IML
Few radial axonal sprouts in
IML but gradient between
IML and OML still visible.
Radial axonal sprouts
prominent and gradient
between IML and OML not
visible
As in grade 2 but radial
axonal sprouts through
IML OML and SGZ
Calretinin Normal pattern: dense band
of axons in immediate SGZ
and IML
Loss of SGZ labelling Diminution of dense band of
axons in SGZ and IML and
axonal sprouts
As in grade 2 but extensive
axonal sprouts in IML and
OML
Calbindin Normal pattern: strong
expression in granule cells,
apical dendrites and mossy
fibres in CA4 and CA3
Patchy loss of expression in
granule cells
Majority of granule cells
negative
Loss of expression
predominates in basal cell
layer
These grading schemes are based on previously used and validated scoring schemes [12–14,23]. Granule cell depletion was not recorded in this
system. GCD, granule cell dispersion; MFS, mossy fibre sprouting; IML, internal molecular layer; OML, outer molecular layer; SGZ, subgranular
zone.
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8 fields along the dentate gyrus were selected per case,
avoiding angles and curvatures. Using Image-Pro soft-
ware (version 6.3, Media Cybernetics, UK), the perpen-
dicular distances of cells (μm) in the dentate gyrus was
measured from a line drawn along the basal granule cell
layer in each image. This was repeated for positively
and negatively stained granule cells in each region. The
mean distance for each group of cells and the differences
between these means was recorded.
Statistical analysis of data between groups was carried
out with SPSS (IBM, version 20) using the Mann-Whitney
test and Pearson’s correlation.
Results
Patterns of HS and GCD
Neuronal loss in the HSD group was predominantly centred
on CA1, rather than CA4 subfield, compared with HSE
cases (Table S1, Table 2; Figure 1A); a significant differ-
ence in the severity of neuronal loss in CA4, but not CA1,
was shown for all HSD (AD + FTLD) compared to HSE
(P < 0.0001). Additionally, in four HSD cases the neuronal
loss in CA1 continued into the subiculum, whereas in HSE
cases, there was an abrupt transition between neuronal
loss in CA1 and the spared subiculum (Figure 1B). In one
HSD case, the neuronal loss was restricted to a segment of
CA1. GCD was less pronounced in the HSD group (Table 2)
with over 80% showing no dispersion, compared to 44%
with no dispersion in the HSE group (Figure 1A,B). GFAP in
HSE (Figure 1D) showed a typical pattern of dense fibrous
gliosis relatively restricted to CA1 and CA4, sparing CA2
and subiculum, with radial glial fibres in the dentate gyrus.
In HSD cases patterns of gliosis were more variable between
subfields, as previously noted [24], but in the majority of
cases a cellular astrocytosis was equally or more pro-
nounced in the subiculum than CA1, and radial gliosis was
less consistently present in the dentate gyrus. In GFAP-δ
immunostained sections in both HSD and HSE prominent
reactive glia were noted in the subgranular zone and CA4
to a greater extent than CA1, as previously described in HSE
[25] (Figure 1C,D); delta-GFAP was therefore less discrimi-
natory than GFAP in the evaluation of HS types.
Dynorphin (Figure 1G,H; Figure 2A–C) In HSE, MFS was
confirmed in five cases, with grade 2 sprouting observed in
four; there was no MFS in any of the controls. Dynorphin
immunolabelling confirmed a normal mossy fibre Ta
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Figure 1. Comparison of hippocampal pathology in hippocampal sclerosis with dementia (HSD; A,C,E,G) and with epilepsy (HSE; B,D,F,H).
In both HSD and HSE neuronal loss in CA1 is the predominant finding (A,B); dispersion of the granule cells is more commonly a feature
accompanying HSE (B, insert) than HSD (A, insert). Astrocytic gliosis with GFAP immunostaining is more variable and cellular, but can be
extensive in HSD and can be equally severe in the subiculum (SC) as in CA1 (C); in HSE there is abrupt, subfield-specific fibrous gliosis
demarcating CA1 and CA4 with sparing of the subiculum (SC) and CA2 region. With delta-GFAP immunostaining in HSD and HSE (insets in
C,D respectively), scattered multi-polar glial cells are prominent in CA4 and near the basal granule cell layer. (E) Normal calbindin staining is
shown in the hippocampus with labelling of granule cell layer, apical dendrites in the molecular layer (ML) and axonal projection in the
mossy fibre pathway to CA4 and CA3. (F) In HSE loss of calbindin expression in the granule cells and their processes is a frequent finding but
with residual interneurones normally labelling (arrow). (G) A normal dynorphin immunostaining pattern in HSD highlighting the mossy
fibre pathway and (H) mossy fibre sprouting in the molecular layer (ML) in HSE. Bar in all approximately equivalent to 2500 μm.
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Figure 2. Dentate gyrus alterations in hippocampal sclerosis in epilepsy (HSE) and dementia (HSD) and control (cont). Dynorphin: (A) In the
majority of HSD cases a normal mossy fibre pathway (grade 0) was visible with labelling of axons in CA4 and no immunopositivity visible in
the molecular layer. (B) Occasional focal sprouting of dynorphin-positive fibres was noted in the inner molecular layer (IML) in three HSD,
(grade 1). (C) Severe and extensive mossy fibre sprouting (grade 2) in the molecular layer (IML) was seen only in HSE cases. Calbindin:
(D) Normal expression in granule cells, dendrites and mossy fibre axons was noted in controls and HSD cases (grade 0) with, (E) loss of
expression in some cases (grade 2). (F) Loss of expression restricted to basal granule cells (grade 3) was noted in three HSD cases without
dispersion and (G) was the commonest pattern in HSE cases with granule cell dispersion. Calretinin: (H) a normal pattern of calretinin
labelling of the axonal plexus on either side of the granule cell layer is shown in controls (grade 0). (I) Loss of the plexus in the subgranular
zone (grade I) and (J) sprouting of fibres in the IML (grade 2) was seen in some HSD cases. (K) In HSE, marked sprouting of fibres in the IML
was a prominent finding (grade 3). Neuropeptide Y: (L) Normal pattern (grade 0) with an axonal plexus in the outer molecular layer (OML)
was seen in controls. Progressively more prominent sprouting of fibres was noted in the inner molecular layer (IML) in HSD cases (grade 1 to
2; I,J). (O) Extensive NPY fibre sprouting through the molecular layer (grade 3) was only observed in HSE. See also Table 1 for details of
descriptions of grading. Bar is equivalent to 300 μm.
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pathway in the majority of HSD cases, with only three
cases showing MFS, one in the AD group (grade 1) and
two in the FTLD group (grade 1) (Table S1, Table 2); no
grade 2 MFS was noted in the HSD group. Of note, in
contrast to the loss of dynorphin labelling of axons and
terminals in the normal mossy fibre projection to CA4
and CA3 in HSE cases with MFS, in HSD these pathways
appeared better preserved. In addition, in one AD case,
plaque-like aggregates of dynorphin were noted in the
CA4 region (Figure 3A), likely corresponding to neuritic
plaques.
Calbindin (Figure 1E,F; Figure 2D–G) Reduced calbindin
expression was noted in the granule cells in all HSE cases,
the predominant pattern being grade 3, with loss of
expression restricted to the more basal cells, as reported
previously [12]. In addition, prominent sprouting of
calbindin-positive fibres through the dentate gyrus was
noted in four cases (Figure 3B) as previously described in
epilepsy [11]. Loss of calbindin was statistically less fre-
quent in HSD (Figure 2D–E), observed in 10 of the 18 cases
(seven from the AD group); Only two cases had a grade 3
pattern with the loss of calbindin in the more basal cells
compared to the distal cells (Figure 2F), but in contrast to
HSE this was not accompanied by GCD (Table 2). Measure-
ments confirmed greater mean differences in the position of
positive vs. negatively labelled granule cells from the basal
layer in HSE than HSD or control groups (mean values 30.2,
10.1 and −3.9 μm respectively; P < 0.05). Sprouting of
calbindin-positive axon fibres was not observed in any HSD
cases.The loss of calbindin in granule cells was also present
in three controls. In all cases with reduced expression of
calbindin in the hippocampal granule cells, normal
interneuronal staining was preserved in the adjacent
cortex.
Calretinin (Figure 2H–K) The predominant pattern in
HSE was grade 3 (4 cases), with prominent sprouting of
fibres and loss of the normal organization (Table 2,
Figure 2K). All controls showed a normal calretinin
pattern (Figure 2H). Abnormal calretinin pattern was
seen in six of the 18 HSD cases (grade 2 (three cases) and
grade 1 (three cases); 4 in the AD group) (Figure 2I–J) but
no grade 3 patterns were observed. In a further case, loss
of calretinin labelling in the dentate gyrus was noted.
Calretinin interneurons appeared generally preserved and
normal in appearance in the adjacent temporal cortex in
AD and FTLD cases.
Neuropeptide Y (Figure 2L–O) The predominant pattern
in the HSE was grade 3, with prominent sprouting of fibres
through the dentate gyrus (Figure 1O); a normal NPY
pattern was seen in only one case. Controls all showed a
normal NPY pattern. In HSD cases, NPY patterns were
abnormal in 11 cases [grade 2 (two cases) and grade 1
(nine cases)] (Figure 1L–N); no grade 3 pattern was
observed. Occasional NPY processes were seen within
senile plaques (Figure 2N).
Statistical analysis confirmed significantly higher
grades of reorganization of calbindin, calretinin, NPY and
dynorphin labelling in the dentate gyrus in HSE compared
to all HSD cases (Table S1 and Table 2). There were strong
correlations between calretinin, NPY and dynorphin
grades (but not calbindin) in the HSE group (all
P < 0.001), but this was less evident in the HSD group (all
P > 0.01). In eight cases in the HSD group, abnormal pat-
terns were observed in the dentate gyrus with two or more
of the four markers and in two cases (one AD, one FTLD)
with all four. In one HSD patient with a history of seizures,
grade 1 patterns were seen with calbindin and NPY but
dynorphin and calretinin patterns were normal. There
were no statistical differences in any of the pathological
measures between HSE patients with or without cognitive
decline, but the numbers in each group were small;
similarly no differences were noted between the HSD AD
and FTLD groups.
An additional finding on NPY sections was the promi-
nent labelling of structures resembling Hirano bodies in 12
HSD cases (8 AD, 4 FTLD) (Figure 3D–E). They were region-
ally restricted to CA1 sector, not seen in other subfields or
the neocortex, and their presence was confirmed on corre-
sponding H&E sections (Figure 3C). NPY-positive Hirano
bodies were observed adjacent to remaining pyramidal
cell somata or ‘free’ in the neuropil (Figure 3D–E). NPY-
positive processes were visible as a ‘tail’-like extension from
some Hirano bodies (Figure 3E) and a central unlabelled
core was noted for some bodies imparting ring-like
structures. In seven cases, Hirano body-like structures
were visible on calretinin-labelled sections but not with
calbindin or dynorphin labelling (Figure 3G). Double-
labelling immunofluorescence of NPY with dendritic
marker, anti-MAP2, confirmed focal co-localization in
some Hirano bodies (Figure 3I), whereas others appeared
lying adjacent to, but distinct from, phosphorylated tau
(AT8)-positive pyramidal cells (Figure 2H). We did not see
Hirano bodies co-localizing with neurofilament-positive
axons (not shown). NPY (or calretinin)-labelled Hirano
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Figure 3. (A) Dynorphin occasionally labelled neuritic plaques in CA4 in Alzheimer’s disease cases. (B) Sprouting of calbindin-positive fibres
was noted in the dentate gyrus in HSE cases but not in HSD. (C) Hirano bodies were noted in CA1 in the control and HSD groups but not in
HSE on H&E preparations. (D) NPY showed intense labelling of numerous Hirano body-like structures in CA1 in HSD in addition to labelling
axons and residual interneurons in this region. They were seen in proximity to negatively labelled pyramidal neurones (D) or free in the
neuropil (E) with occasional body showing a tail like process (arrowhead in E). (F) In HSE cases, only interneurons and extensive fibre
networks were labelled in CA1 with NPY. (G) Weaker labelling of Hirano bodies was noted with calretinin. (H) Con-focal microscopy showed
no co-localization of NPY-positive Hirano-like bodies with AT8 positive pyramidal cells in CA1; double-labelling with dendritic marker MAP2
(I) showed approximation of NPY Hirano bodies to neuronal process and dendrites. In addition, a peripheral rim of NPY positivity was
appreciated in some Hirano bodies with a hollow central core (arrowhead). Bars in A,C,D,E,G = 75 μm, B,F = 140 μm, H = 20 μm,
I = 20 μm.
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bodies were not seen with any of the epilepsy cases (even up
to age 87 years), where only normal NPY interneurons
were observed (Figure 3F). NPY-positive Hirano bodies
were noted in CA1 in three controls (57–68 years).
Discussion
Hippocampal sclerosis is a generic term used for the
description of neuronal loss and gliosis, preferentially
involving hippocampal subfields. Although historically
associated with epilepsy, there has been increasing recog-
nition in recent years of a similar pathological change
arising as a ‘pure’ lesion in elderly, or in association with
a neurodegenerative condition. These different clinical
groups of HS have not been directly compared histologi-
cally. Identification of different cellular alterations would
be helpful in their diagnostic evaluation, would allow a
deeper understanding of different mechanisms of cell
degeneration that may be operating, and would enable the
identification of pathological alterations that correlate
with specific clinical symptoms, for example cognitive dys-
function vs. hippocampal epileptogenicity.
HSE and HSD may both be bilateral or asymmetrical
between hemispheres [23,26], with no clear predilection
for left or right and may vary in the extent of its longitu-
dinal involvement along the hippocampal axis (Table 3).
In this present study we focused on one level of the
hippocampal body from each case, representative of the
sclerosis, for detailed analysis. We observed differences
between HSD and HSE in the distribution of cell loss
Table 3. Summary of the clinical, pathological and aetiological features that enable the distinction of HSE from HSD
Feature HS in epilepsy (HSE) HS in dementia and ageing (HSD)
Clinical context
Typical presentation Childhood to young adulthood
Seizure syndromes, particularly mTLE
Adult to the ‘oldest-old’
Dementia, cognitive decline.
Prevalence Surgical epilepsy series ∼35%
PM epilepsy series ∼30–40%
In elderly between ∼3–24%
‘Pure’ HS in 23% of dementia cases
Distribution
Bilaterality Bilateral in ∼48–56% in epilepsy PM series (all
syndromes including TLE)
Bilateral in ∼45–60%
Longitudinal extent Localized or extensive along rostro-caudal length [14] Localized or extensive along rostro-caudal
length [26]
Pattern of HS
Distribution of neuronal
loss and gliosis
CA1: Typically severe cell loss
Subiculum: Spared
CA4/3: Neuronal loss
Granule cell dispersion in ∼50%
CA1: Extensive to patchy loss
Subiculum: Often cell loss
CA4: Spared
Granule cell dispersion less evident
Circuitry reorganization
Mossy fibre system Mossy fibre sprouting typically present and extensive Mossy fibre sprouting usually absent
If present mild and focal
Calbindin expression Reduced expression in granule cells, particularly basal
cells
Reduced expression in granule cells may occur
NPY expression Resistance of CA1 interneurones
Prominent sprouting in DG
Loss of CA1 interneurones
Mild sprouting in DG in some
Calretinin Reorganization of DG networks Mild reorganization of DG networks may be present
Patho-mechanisms
Causes of neuronal loss Seizure mediated/excitotoxic neuronal injury Heterogenous causes:
‘Ageing’
Vascular brain injury
AD, FTLD
Synucleinopathies with HS
Contribution of
TDP-43, ApoE
TDP-43 not identified in surgical unilateral cases
[17,59] or bilateral HSE at PM [5]
ApoE ε4 associated with earlier onset [60] in some but
not all studies [61]
TDP-43 inclusions in up to 93% of pure HSD
[17,47] [26]
HSD not associated with ApoE ε4 [17,47]
mTLE, mesial temporal lobe epilepsy; DG, dentate gyrus; HS, hippocampal sclerosis; PM, post mortem; AD, Alzheimer’s disease; FTLD, fronto-
temporal lobe dementia.
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between subfields at this coronal level. The neuronal
loss in HSD predominantly involved CA1 sector, typically
extending into the subiculum in several cases, but sparing
CA4. This distribution of neuronal loss has been previ-
ously reported in studies of HSD [17,26]. This contrasts to
the classical pattern of atrophy in HSE, where CA1 damage
is accompanied by CA4 neuronal loss with an abrupt
transition between the neuronal loss and gliosis in CA1
and the adjacent well-preserved subiculum [1]. We also
showed that GCD, a common alteration in HSE [27,28],
was rare and mild in HSD. GCD has been associated with
both an early age of onset of seizures and with the severity
of CA4 neuronal loss [27,29]. An atypical pattern of HSE
shows predominant involvement of CA1 only, and has
been associated with a later age of onset of seizures
[30,31]. These observations could indicate an age-
dependent vulnerability of the dentate gyrus and CA4,
which is spared in older onset HSE and HSD cases.
Studies of HS in epilepsy series have focussed on cellular
alterations that could render this region hyper-excitable.
MFS was first observed in experimental seizure models as
an early event [8] and has been suggested to be critical to
the development of recurrent seizure activity associated
with HSE, through enhanced excitability and/or synchro-
nization of granule cells. We have previously shown, in a
PM series of HSE cases, that MFS can persist into the ninth
decade, even with the remission of seizures [23]. There-
fore, there is an alternative argument that MFS is an
epiphenomenon or response to seizures, rather than a
primary epileptogenic process. In one HSD patient in the
present series in whom occasional clinical seizures were
documented, MFS was not present and in other HSD cases,
MFS was rare and mild. In elderly patients and those with
cognitive decline, partial seizures may be unrecognized
[32,33] because EEG may not be performed as a routine
test, therefore we cannot entirely exclude ‘sub-clinical’
seizure activity as the mechanism for the focal MFS seen in
HSD. Notwithstanding, the findings favour the view that
severe MFS is linked with hippocampal excitability and is
therefore a relatively reliable histological marker for HSE.
Alterations to dentate gyrus interneurones have been
extensively studied in HSE, in surgical and PM tissues. Cell
loss, cyto-morphological alterations and axonal sprouting
represent the more common findings (for review see [34])
and these stereotypical alterations parallel the principal
neuronal loss in established cases [14]. Interneuronal
alterations are not exclusive to HSE associated with mTLE,
and can be seen with other epilepsy syndromes [14,23]. It
is the axonal sprouting of interneurons that is considered a
more functionally significant process in relation to network
changes, correlating with synaptic re-organization [9,11].
These alterations are easily recognized and reliably graded
in tissue sections, as in the present study, and sprouting of
these inhibitory networks in the dentate gyrus tend to
occur in synchrony with the sprouting of excitatory net-
works (the mossy fibres) [23]. We identified significantly
more cases with interneuronal sprouting using calretinin
and NPY labelling in HSE than HSD cases with more exten-
sive sprouting (corresponding to the higher grades) as well
as sprouting of calbindin-positive fibres, which was exclu-
sive to HSE cases.
In previous studies of the hippocampus in AD, a reduc-
tion of NPY axons in the dentate gyrus was demonstrated,
with clusters or beaded clumps of axons, some associated
with neuritic plaques [35]. We also confirmed occasional
association of NPY fibres in addition to dynorphin fibres,
associated with neuritic plaques in AD. In an APP-mutant
model of AD, ectopic expression of NPY was shown in
granule cells as well as sprouting of NPY fibres in the
molecular layer from hilar NPY neurones [36]. The
authors proposed that this represented amyloid β-
mediated neuronal excitatory activity and subsequent
re-modelling of inhibitory circuits that resemble altera-
tions in experimental epilepsy models [36]. Our study sup-
ports the notion that subtle inhibitory neuronal network
alterations may occur in HSD, similar to HSE. As for our
observations with MFS in HSD, we cannot exclude subclini-
cal epileptic activity or un-recognized seizures and local
hippocampal excitability as a cause for these alterations.
Furthermore, in eight of the HSD cases with MFS and
interneuronal alterations, parallel changes were seen with
more than one marker, supporting systematic network
re-organization occurring in the dentate gyrus in some
cases. A further consideration is that the cellular pathology
occurring in HS with neurodegeneration could inhibit
these synaptic reorganizational changes that are more
profuse in HS with epilepsy.
Loss of calbindin expression in the dentate granule cells
has been shown in experimental AD models (human APP
transgenic mutant) as well as in PM series [37–39] and
correlated with both cognitive deficits and the abundance
of amyloid β protein [40]. Loss of calbindin in AD was the
most frequent abnormality, observed in 70% of AD HSD
compared to 37% in the FTLD group in this study. It is also
known that an age-related decline of calbindin in granule
cells occurs, which has been associated with impaired
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hippocampal function [41], and was noted in three con-
trols in the current study. We recently reported a pattern
of calbindin loss from the basal granule cells in HSE asso-
ciated with early onset of seizures, which was the most
prominent pattern also in the present HSE cases. This
pattern was noted in only two of the HSD cases. It has been
proposed that loss of calbindin causes changes to the
intrinsic excitability of granule cells in addition to its
roles in memory impairment [42]. A reduction of CA4
calretinin positive neurones has also been shown in
experimental [43] and AD cases [44], although less is
known about hippocampal interneuronal alterations in
FTLD [45]. Calretinin axonal networks have not been
previously studied in HSD; they were mildly altered in a
minority of cases in the present series.
HSD may be encountered as a ‘pure’ or isolated pathology
in the elderly, associated with dementia or an amnestic
syndrome and in the absence of typical neuronal inclu-
sions associated with AD or FTLD or vascular disease. This
may represent a relatively unrecognized cause of demen-
tia, in the oldest age groups [46] and is associated with
TDP-43 immunoreactive inclusions in the granule cells
[17,26,47]. The present study was limited by not having
‘pure’ HSD cases available for comparison to HSE. Neverthe-
less from a practical viewpoint, when HS is encountered at
PM examination in the elderly, the pattern of neuronal loss
in addition to assessment of any neurodegenerative
features (including TDP-43), interneuronal markers and
mossy fibre alterations may help to identify the cause of the
sclerosis (as summarized in Table 3).
A serendipitous finding in the study was the labelling of
Hirano bodies in AD and controls for NPY and, to a lesser
extent, calretinin. The origin and physiological function of
Hirano bodies in ageing and AD has remained elusive
since their first recognition 40 year ago. They are filamen-
tous, paracrystalline inclusions, comprising many pro-
teins including actin, co-filin and alpha-actinin [48,49].
The focal overlap of expression of the NPY-positive Hirano
body with MAP2 supports the view that some are within
dendrites, as previously reported [48,50], whereas others
may be axonal. It is estimated that CA1 pyramidal cells are
supported by 16 types of GABA-ergic neurones [51],
including NPY interneurons, many forming a connected
‘pair’ with a single CA1 pyramidal cell [52]. NPY-positive
interneurons in CA1 are bi-stratified cells with axon termi-
nals on the dendritic domains of CA1 pyramidal cells,
mediating inhibition via GABAA receptors [51,53]. The
NPY cell dendrites extend into the stratum oriens and
radiatum and, in turn, receive excitatory input from
pyramidal cell collaterals.
Previous studies of CA1 NPY interneurones in AD
described the most dramatic changes occurring in this
subfield with surviving cells bearing shortened dendrites
(‘dendritic stumps’) and damaged thick axons, although
labelling of Hirano bodies was not described [35,54]. In
the PS1/APP transgenic model of AD, loss of NPY-
somatostatin co-labelled neurones in CA1 was an early
finding, demonstrating a specific vulnerability of these
cells in AD, which preceded the pyramidal cell loss [55].
In HSE by contrast, relative resistance of NPY-positive
interneurons in CA1 has been shown [56] in epilepsy
models and in human MTLE/HS cases, despite the exten-
sive loss of CA1 pyramidal cells and hilar NPY cells [31].
These observations highlight a different time-course for
loss of CA1 NPY interneurons in HSD due to AD vs. HSE.
Recent studies have shown PSD-95, a structural protein of
excitatory synapses, to label a proportion of Hirano bodies
[50]; a further study showed co-localization of Hirano
bodies with GluR1 and R2 AMPA receptors in the vicinity
of pyramidal cells [57]. It has been postulated Hirano
bodies represent aberrant formation of post-synaptic
structures in response to distal synaptic destruction [50].
In experimental systems, Hirano bodies have been shown
to be both protective against neurodegeneration mediated
by tau or APP [58] as well as to inhibit normal cellular
function [49]. One explanation is that Hirano bodies arise
in residual NPY neurones in AD as a compensatory, but
cellular degenerative response, to the ongoing imbalances
between reciprocal inhibitory and excitatory networks as
the disease progresses. The potential functional signifi-
cance of Hirano bodies is therefore of interest and requires
further study.
In summary, reorganization of excitatory and inhibi-
tory networks in the dentate gyrus is more typical of HSE.
Subtle alterations may occur in HSD, which could be a
result of increased hippocampal excitability, including
unrecognized seizure activity. An unexpected finding was
the identification of NPY-positive Hirano bodies in HSD but
not HSE, which may be a consequence of the relative
vulnerabilities of interneurons in these conditions.
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